• Contact Us

Columbia University
Irving Medical Center
Neurological Institute

710 West 168th Street, 3rd floor
(212) 305-1818

Clinical Trials

Clinical Trials Currently Recruiting (May 2023)

Alzheimer’s Disease: INVOKE-2 AL002-2 (Alector Inc)
A Phase 2 Study for Safety and Tolerability of AL002.
Phase 2. IV Infusion. Every 4 weeks. Duration: about 52-96 weeks. NCT04592874.
AD. MMSE: ≥20. Age: 50-85.
Procedures include: MRI (total: 3), LP (total: 3), Amyloid PET scan (total: 3).
(Dr. Honig) Call Katrina Cuasay 212-305-2077

UPCOMING:Mild Cognitive Impairment/Early Onset Alzheimer’s Disease: Focused UltraSound (NIA)
Non-invasive Blood-brain Barrier Opening in Alzheimer's Disease Patients Using Focused Ultrasound
Phase 1. Duration:5 visits. NCT04118764.
Amnestic Mild Cognitive Impairment/Alzheimer’s Disease. MMSE: 12-26. Age: ≥50.
Procedures include: MRI, head ultrasound.
(Dr. Honig/Dr. Konofagou) Call Katherine Liu 212-342-1612

UPCOMING:Healthy Volunteers/Mild Cognitive Impairment/ Alzheimer’s Disease: [18F]APN-1607 (Aprinoia)
Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients Compared With Healthy Subjects.
Phase 2. PET imaging using [18F]APN-1607. Two visits (PET only). Duration: about 1 month. NCT04141150.
Controls/MCI/AD. MMSE: ≥ 27 (Controls), 24-30 (MCI), 10-26 (AD). Age: 50-85.
(Dr. Honig) Call Katrina Cuasay 212-305-2077

Preclinical Alzheimer’s Disease: AHEAD 3-45 BAN2401 (Eisai Inc.)
A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical AD and Elevated Amyloid and Also in Participants With Early Preclinical AD and Intermediate Amyloid.
Phase 3. Intravenous infusion every 2 or 4 weeks depending on the assigned arm. Duration: about 4 years. NCT04468659.
Preclinical AD. MMSE: ≥ 27. Age: 55-80.
Procedures include: MRI (total: 13), Amyloid PET (total: 3), Tau PET (total: 3), LP (optional)
(Dr. Bell) Call Chrismary De La Cruz 212-305-7661

Mild Cognitive Impairment: VALMCI valacyclovir (Alzheimer’s Association)
Anti-viral therapy in Mild Cognitive Impairment.
Phase 2. Oral Medication. Twice daily. Duration: 52 Weeks (12 months). NCT04710030.
Early and Late Mild Cognitive Impairment; positive screening tests results for antibodies to HSV1 or HSV2. MMSE: 23-30. Age: 50-95.
Procedures include: MRI (total: 2), Amyloid PET scan (total: 2). Flobetapir PET scan done at screening as part of the study to determine eligibility
Procedures include: MRI (total: 2), Amyloid PET scan (total: 2).
(Dr. Devanand) Call Memory Disorders Clinic: Betty Ostrager 646-774- 7204

Alzheimer's Disease: S-CitAD escitalopram (NIA)
Escitalopram for Agitation in Alzheimer’s disease.
Phase 3. Psychosocial Intervention and Oral Medication. Duration: 24 Weeks (6 months). NCT03108846.
Alzheimer's disease (AD) with agitation. MMSE: 5-28. Age: 55-95.
(Dr. Devanand) Call Jamie Graff 646-774-8638

Dementia with Lewy Bodies: COG1201 CT1812 (NIH/NIA; Cognition Therapeutics)
Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects with Mild to Moderate Dementia with Lewy Bodies.
Phase 2. Oral Medication. Once daily. Duration: about 6 months. NCT05225415.
DLB. Age: 50-85. MMSE:18-27.
Procedures include: MRI (if not done in past year), skin biopsies, optional LPs.
(Dr. Honig) Call Katrina Cuasay 212-305-2077

UPCOMING: Dementia with Lewy Bodies: EIP21-NFD-504 neflamapimod (EIP Pharma)
A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Dementia with Lewy Bodies (DLB)
Phase 2b. Oral Medication. Once daily. Duration: about 23 weeks.
DLB. Age: >=55; CDR 0.5 or 1.0.
Procedures include: DaT Scan (if not done)
(Dr. Honig) Call Katrina Cuasay 212-305-2077

Frontotemporal Dementia: INFRONT-3 AL001-3 (Alector Inc)
A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia.
Phase 3. IV Infusion every 4 weeks. Duration: about 96 weeks. NCT04374136.
FTD. Carrier of progranulin gene mutation and at risk of developing FTD symptoms as evidenced by a biomarker or diagnosed with FTD. CDR 0, 0.5, 1, or 2. Age: 18-85.
(Dr. Honig) Call Katrina Cuasay 212-305-2077

Observational Studies Currently Recruiting (May 2023)

UPCOMING:Mild Cognitive Impairment or Dementia: New IDEAS
New IDEAS: Imaging Dementia-Evidence for Amyloid Scanning Study.
Mild Cognitive Impairment (MCI) or dementia. Medicare as primary insurance. NCT04426539.
Age: ≥18.
(Dr. Honig) Call Katrina Cuasay 212-305-2077

Mild Cognitive Impairment/Early Onset Alzheimer’s Disease/Normal Cognition: LEADS (NIH/NIA)
Longitudinal Early Onset Alzheimer’s Disease
Duration: 2 years, yearly visit. NCT03507257.
Mild Cognitive Impairment/Early Onset Alzheimer’s Disease/Normal Cognition. CDR 0, 0.5 or 1.0 (MCI/AD). Age: 40-64.
Procedures include: MRI, Amyloid and Tau Pet scan, optional LP.
(Dr. Honig) Call Arlene Mejia 212-305-9168

Mild Cognitive Impairment/Alzheimer’s Disease/ Normal Cognition: ADRC clinical core (NIH/NIA)
Alzheimer’s Disease Research Center Clinical Core
Duration: 2 hours visit (in person). Visits are every year for the duration of the study.
Mild Cognitive Impairment/Mild Alzheimer’s Disease/Normal Cognition. Age: 55-90.
Procedures include: MRI, LP.
(Dr. Noble) Call Naara Ramirez Estevez 212-305-9971

Healthy Volunteers with Cognitive Complaints: Diverse VCID (NINDS)
Diverse Vascular Contributions to Cognitive Impairment and Dementia
Duration: 3 years, yearly visit
Subjective memory complaints, stroke free, CDR 0 or 0.5; Age: 65-90; must co-enroll with ADRC
Procedures include: fasting blood draw, structural MRI, lifestyle questionnaires, list learning task
(Dr. Brickman) Call Christiane Hale 646-317-4072

Mild Alzheimer's Disease/Normal Cognition: AD Autoimmune (NIH/NINDS)
Autoimmune features in neurodegenerative disorders
Duration: 1 to 2 visits. 1.5hrs per visit. NCT04239079.
Mild Alzheimer's Disease/Amnestic Mild Cognitive Impairment/Normal Cognition. AD: MMSE: 20-26, CDR 0.5-1. Age: ≥55.
Procedures include: 100ml blood draw.
(Dr. Marder) Call Kim Tran 469-739-1748

Amnestic, visual, and language variants of Mild Cognitive Impairment/AD: ADVISe (NIH/NIA)
Longitudinal imaging of microglial activation in different clinical variants of Alzheimer's disease
Duration: 2 years, baseline visits and 2 year follow up. NCT04576793.
Amnestic Mild Cognitive Impairment/Amnestic Alzheimer's Disease/Posterior Cortical Atrophy/Logopenic Variant Primary
Progressive Aphasia/Normal Cognition. CDR 0, 0.5 or 1.0. Age: 50+.
Procedures include: MRI, Amyloid, Tau, and Inflammation PET scans, LP.
(Dr. Small/Noble) Call Aubrey Johnson 212-305-9079

Mild Cognitive Impairment/Alzheimer's Disease: PAM (NIH/NIA)
Discovery and validation of genetic variants affecting microglial activation in Alzheimer's disease
Duration: 5 years, baseline MRI/PET scan and 4 year follow up for blood draw/cognitive testing.
aMCI/AD/Normal Cognition (with prior LP or amyloid PET scan). CDR 0, 0.5 or 1.0. Age: ≥ 50.
Procedures include: MRI, Inflammation PET scan. 
(Dr. Philip De Jager) Call Aubrey Johnson 212-305-9079

Alzheimer’s Disease: DIAN (NIH/NIA)
Dominantly Inherited Alzheimer Network
Duration: Years. Every 1 to 3 years visits. NCT00869817.
Family members of a person with AD (proband) due to PSEN1, PSEN2, or APP mutations. MMSE: any. Age: ≥18; younger but no more than 10 years younger than proband’s AAO.
(Dr. Noble) Call Naara Ramirez Estevez 212-305-1894

Alzheimer’s Disease: EFIGA (NIH/NIA)
Genetic Study of Alzheimer’s Disease in Caribbean Hispanics
Duration: 1.5 hours visit (in person). Visits are every 2 years for the duration of the study. Hispanic individuals or families with or without memory problems willing to participate. Age: Affected any age. Unaffected 50 or older.
(Dr. Mayeux) Call Angel Piriz 212-305-2309

Alzheimer’s Disease: AD Family Based Study (FBS) (NIH/NIA)
Late and Early Onset Alzheimer’s Disease
Duration: 1.5 hours visit (in person/over the phone). Every 2 years visit for the duration of the study. Any ethnic background families with AD family history and/or with multiple affected alive members willing to participate.
Age: Affected any age. Unaffected 50 or older.
(Dr. Mayeux) Call Gelanys Castro 212-305-5909, Penelope Baez (For Early onset participants) 212-305-2349

Alzheimer’s Disease: DAWN (NIH/NIA)
Genetic Study of Alzheimer’s Disease in Hispanics and African Americans.
Duration: 1.5 hours visit (in person/over the phone).
Hispanic or African American individuals with and without memory problems.
Age: Affected and Unaffected 50 or older
(Dr. Reitz) Call Jenny Chavez 212-342-3029
(Dr. Tosto) Call Jennifer Cespedes 646-317-9317 email: dawnstudy_neuro@cumc.columbia.edu

Alzheimer’s in African American Families (NIH/NIA)
Recruiting African American families with at least one with cognitive impairment plus another family member willing to participate.
Duration: 1.5 hours visit (in person/over the phone).
Every 2 years visit for the duration of the study.
Age: Affected any age. Unaffected 50 or older.
(Dr. Reitz ) Call Jenny Chavez 212-342-3029

Alzheimer’s Disease: Asian Cohort Alzheimer’s Disease (ACAD) (NIH/NIA)
Late Onset Alzheimer’s Disease
Duration: 2 hours visit (in person/over the phone). Every 2 years visit for the duration of the study. Chinese, Korean or Vietnamese individuals with AD family history with or without memory problems willing to participate.
Age: Affected 60 and older.
(Dr. Mayeux) Call Fangcong (Nini) Cheng: 332-257-4055

Dementia with Lewy Bodies: Targeting Lewy Body Pathology (NIH/NINDS)
Targeting Lewy Body Specific Pathology Using Biomarkers
Duration: 3-5 years.
Mild Cognitive Impairment due to Dementia with Lewy Bodies/Dementia with Lewy Bodies/Parkinson’s Disease Dementia.
Procedures include: optional LP.
(Dr. Marder/Dr. Honig) Call Helen Mejia-Santana 212- 305-9183

Frontotemporal Dementia: ALLFTD (NIH/NIA/NINDS)
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration Protocol
Duration: 3-6 hour visits, for 1-5 years. NCT04363684
National consortium enrolling: Behavioral Variant Frontotemporal Dementia/Non-Fluent Variant Primary Progressive Aphasia/Semantic Variant Primary Progressive Aphasia/ Frontotemporal Dementia-Amyotrophic Lateral Sclerosis.
Also enrolling asymptomatic members of families with mutation in MAPT, GRN, C9orf72, or strong family history of FTLD.
Age: ≥18, CDR 0, 0.5, 1, or 2.
Procedures include: MRI, optional LP, optional genetic testing.
(Dr. Honig) Call Katrina Cuasay 212-305-2077

Programs Currently Recruiting (May 2023)

Arts and Minds
The Studio Museum in Harlem, New York Historical Society, and El Museo del Barrio
Excluded: persons with depression (only), cognitively normal persons, and patients with dementia. Spanish-speakers are welcome.
Participants will explore the world of art and culture in these interactive 75-minute programs.
(Dr. Noble) Call Carolyn Halpin-Healy 646-755-3726

A Friend for Rachel
A companionship program
MCI, early AD, early PPA, FTD (if not too behavioral), early DLB (if no hallucinations). Must be mobile and able to go out without an aide.
Participants will spend a few hours a week with their student friend either exploring NYC or staying near home.
Call Jill Goldman 212-305-7382